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Yann Jamin, PhD, Jane Halliday, PhD,z John C. Waterton, PhD,z and Simon P. Robinson, PhDAbstract: The aim of this study was to use the combined carbogen-
ultrasmall superparamagnetic iron oxide (CUSPIO) magnetic resonance
imaging (MRI) method, which uses spatial correlations in independent
susceptibility imaging biomarkers, to investigate and compare the impact
of tumor size and anatomical site on vascular structure and function
in vivo. Mice bearing either subcutaneous or orthotopic PC3 LN3 prostate
tumors were imaged at 7 T, using a multi-gradient echo sequence to
quantify R2
, before and during carbogen (95% O2/5% CO2) breathing,
and subsequently following intravenous administration of USPIO
particles. Carbogen and USPIO-induced changes in R2
 were used to
inform on hemodynamic vasculature and fractional blood volume (%),
respectively. The CUSPIO imaging data were also segmented to identify
and assess five categories of R2
 response. Small and large subcutaneous
and orthotopic tumor cohorts all exhibited significantly (P< 0.05) differ-
ent median baseline R2
, DR2

carbogen, and fractional blood volume.
CUSPIO imaging showed that small subcutaneous tumors predominantly
exhibited a negative DR2

carbogen followed by a positive DR2

USPIO,
consistent with a well perfused tumor vasculature. Large subcutaneous
tumors exhibited a small positive DR2

carbogen and relatively low fractional
blood volume, suggesting less functional vasculature. Orthotopic tumors
revealed a large, positive DR2

carbogen, consistent with vascular steal, and
which may indicate that vascular function is more dependent on site of
implantation than tumor size. Regions exhibiting significant DR2

carbogen,
but no significant DR2

USPIO, suggesting transient vascular shutdown over
the experimental timecourse, were apparent in all 3 cohorts. CUSPIO imaging
can inform on efficient drug delivery via functional vasculature in vivo, and on
appropriate tumor model selection for pre-clinical therapy trials
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T he combined carbogen ultrasmall superparamagnetic iron oxide(USPIO) imaging protocol (CUSPIO) combines two magnetic
resonance imaging (MRI) techniques, intrinsic susceptibility contrast
MRI and contrast-enhanced susceptibility MRI with USPIO particles.
The transverse relaxation rate (R2
) slows with high oxygen content
gas breathing, which decreases the ratio of deoxyhemoglobin (para-
magnetic) to oxyhemoglobin (diamagnetic) in blood. The resulting
change in R2
, DR2

carbogen, reflects changes in oxygenation and the
hemodynamic response in functional vasculature. Intravenous injec-
tion of USPIO particles increases R2
 in tissue surrounding blood
vessels that are perfused with blood plasma at the time of injection.
With a known blood concentration of USPIO particles,DR2

USPIO can
be used to calculate fractional blood volume. Given the difference in
size of erythrocytes and USPIO particles, (6 and 0.03mm, respect-
ively),1 thevolume of distribution influenced by hyperoxia andUSPIO
is likely to differ, with small vessels offering preferential access to
USPIO particles. By combining, into a single imaging session, sequen-
tial measurements ofDR2
 induced by carbogen breathing andUSPIO
particles, greater information about vascular function and structure can
be deduced than could be achieved using each technique individually.2
The CUSPIO protocol achieves this by implementing a novel seg-
mentation scheme, in which DR2
 estimates are compared and
assigned to 1 of 5 response categories. Our previous work has shown
that these categories provide distinct information about vascular
function, the spatial distribution of plasma perfusion and transient
hypoxia, and that these biomarkers can inform on tumor response to
anti-angiogenic therapy.2,3
The clinical relevance of rodent models in both fundamental
cancer research and drug development has been an ongoing debate
for many years. The inadequacies and limitations of ectopic (sub-
cutaneous) models are frequently highlighted, but there has also been
a historical reluctance to adopt more complex models in cancer
research.4–6 Today, more sophisticated orthotopically propagated
tumor models, in which cancer cells are implanted and grown within
the organ from which they were derived, and genetically engineered
mouse (GEM) models, in which tumors are driven by the expression
of the target of interest and arise spontaneously within the native
tissue of origin, are being increasingly exploited.7,8 These models
more faithfully emulate human tumor growth, tumor-host stromal
interactions and vasculature, metastatic potential, and therapeutic
response in vivo. The systematic use of orthotopic and GEM models
in pre-clinical cancer research demands noninvasive anatomical and
functional imaging methods for the longitudinal monitoring of tumor
progression and response, which can also accurately inform on key
hallmarks of cancer, such as angiogenesis. We have previouslywer Health, Inc. All rights reserved.
demonstrated the use of several MRI strategies with which to assess,
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ectopic, orthotopic, and GEM models.9–15
The purpose of this study was to exploit CUSPIO imaging to
investigate vascular function and structure in small and large sub-
cutaneous, and orthotopically propagated PC3 LN3 prostate xeno-
grafts, and compare the differences in these characteristics between
the different models.
METHODS
Cell Culture
Human PC3 LN3 prostate tumor cells, originally generated
in-house from lymph node metastases arising in nude mice
bearing orthotopic PC3 tumors,16 were cultured in T75 cm3 flasks
(Corning Life Sciences, High Wycombe, UK) in Dubbecco’s
Modified Eagles Medium (DMEM; Invitrogen, Paisley, UK)
supplemented with 10% (v/v) fetal bovine serum, 5mM L-gluta-
mine,100 IU/mL penicillin, and 100mg/mL streptomycin (all Invi-
trogen). Cells were maintained at 378C in a humidified 5% CO2
atmosphere.
Tumor Propagation
All experiments were performed in accordance with the local
ethical review panel, the UK Home Office Animals (Scientific Pro-
cedures) Act 1986, the United Kingdom National Cancer Research
Institute guidelines for animal welfare in cancer research,17 and the
Animal Research: Reporting of In Vivo Experiments (ARRIVE)
guidelines.18 Male NCr nude mice under isoflurane anesthesia were
injectedwith 1 106 PC3 LN3 cells subcutaneously on the right flank,
or 1 105 cells into the ventral prostate gland.9 The subcutaneously
inoculated animals were randomized into 2 groups of 6 mice, to be
imaged as small and large tumors. Animals from group 1 were imaged
1 week later, and animals from group 2 were imaged 3 weeks later.
Orthotopically inoculated animals were monitored by palpation and
imaged after 3 weeks (n¼ 5). No adverse effects were observed in any
of the mice, and none excluded from the study.
Combined Carbogen-Ultrasmall Superparamagnetic
Iron Oxide Imaging Protocol
Tumor-bearing mice were anesthetised by an intraperitoneal
injection of 10mL/kg of fentanyl citrate (0.315mg/mL) along with
fluanisone (10mg/ml) (Hypnorm; Janssen Pharmaceutical, High
Wycombe, UK), midazolam (5mg/mL) (Hypnovel; Roche, Burgess
Hill, UK), and sterile water (1 : 1 : 2). A lateral tail vein was cannu-
lated with a 27G butterfly catheter (Venisystems; Abbot Labora-
tories, Maidenhead, UK) for remote administration of USPIO
particles. A nosepiece was positioned for delivery of air or carbogen
(95% O2/5% CO2) at a flow rate of 1L/min. During MRI, all mice
were restrained using dental paste in order to limit respiratory motion
artefacts.19 Awarm air blower was used to maintain the animal’s core
temperature at 378C within the magnet bore.
MRI was performed on a 7-T horizontal bore microimaging
system (Bruker, Ettlingen, Germany) using a 3 cm birdcage coil.
T2-weighted turboRARE images (echo time TE¼ 36ms, repetition
time TR¼ 4200ms, 2 averages) were first acquired from contiguous
1mm thick axial slices for tumor localization and volume determi-
nation. Next, 2 sets of multigradient echo (MGE) images (TE¼ 6 to
28ms, 4ms echo spacing, TR¼ 200ms, flip anglea¼ 458, 8 averages,
acquisition time AQ¼ 3min 37 s) were acquired from 3 axial 1mm
slices through the tumor center while the mouse breathed air. The gas
supply was then switched to carbogen, and following a 10-minute
transition period, a further identical MGE image set was acquired. The
gas supply was then reverted back to air and, after another 10-minute Copyright © 2016 Wolters Kluw
transition period, another MGE image set was acquired. A final MGE
238 | www.topicsinmri.comimage set was then acquired 1minute after intravenous injection of
150mmol/kg USPIO particles (ferumoxtran-10, Sinerem; Guerbet,
Villepinte, France).
Tumor volumes were determined using segmentation from
regions of interest (ROIs) drawn on T2-weighted images for each
tumor-containing slice, using in-house software (Imageview, devel-
oped in IDL; ITT Visual Information Systems, Boulder, CO). MGE
data were analyzed using a Bayesian maximum a posteriori
approach.20 This modeled the MGE signal magnitude as a single
exponential decay and took into account its Rician distribution.
Furthermore, it enabled estimates of DR2
 uncertainty to be defined
and the probability that a given DR2
 estimate was significantly
greater than or less than zero. Thus, the number of voxels within the
tumor ROI with an uncertainty of less than 0.05ms1 and with a
significant (P< 0.05) change in R2
 induced by carbogen (DR2

carb-
carbogen) and/or USPIO particles (DR2

USPIO) were calculated. Frac-
tional blood volume (j, %) was quantified from theDR2

USPIO data as
previously described.21 The increase in blood susceptibility caused
by the USPIO particles was extrapolated from a previously published
value for a dose of 200mmol/kg.22
RGB maps were then generated, with the red channel desig-
nated to voxels with a positive DR2

carbogen, the blue channel to
voxels with negative DR2

carbogen, and the green channel to positive
DR2

USPIO. It was assumed that DR2

USPIO could only be positive,
and negative values were assumed to be a result of uncertainty in R2

estimates. Regions with both negative DR2

carbogen and positive
DR2

USPIO therefore appeared cyan (blue þ green), and regions with
both positive DR2

carbogen and positive DR2

USPIO appeared yellow
(red þ green).
Histological Assessment of Tumor Perfusion
Following MRI, Hoechst 33342 (15mg/kg in water; Sigma,
Poole, UK) was administered intravenously via a lateral tail vein.
Hoechst 33342 is a nuclear dye that stains the cells lining blood
vessels that are perfused at the time of injection, affording a measure
of functional tumor vasculature.23 Mice were killed 1minute after
injection of Hoechst 33342 and tumors rapidly excised and snap
frozen over liquid nitrogen. Contiguous 10mm frozen sections at
three levels through each tumor were cut on a cryotome in approxi-
mately the same plane as was imaged with MRI. Sections were fixed
in ice-cold acetone for 10minutes before being mounted in phos-
phate-buffered saline. Hoechst 33342 fluorescence signals from
whole tumor sections were then recorded at 365 nm using a motorized
scanning stage (Prior Scientific Instruments,Cambridge,UK) attached
to a BX51 microscope (Olympus Optical, London, UK) driven by
CellP (Soft Imaging System,Munster, Germany). The area of Hoechst
33342 fluorescence as a percentage of the total tumor area mean
Hoechst perfused area (mHPA)] was then calculated using CellP.
Statistical Analysis
All data are reported as mean of median values 1 standard
error of the mean unless otherwise stated. Statistical significance was
determined using Student’s 2-tailed unpaired t test assuming 2
samples of the population with equal variance. A P value
of< 0.05 was considered significant.
RESULTS
MRI-Derived Tumor Volumes
The small tumor cohort of subcutaneous PC3 LN3 xenografts
had a mean volume of 44 9mm3, which was significantly smaller
than the large subcutaneous tumor cohort (563 40mm3, P< 0.01).
The orthotopically propagated PC3 LN3 xenografts had a mean
3er Health, Inc. All rights reserved.
volume of 377 134mm .
 2016 Wolters Kluwer Health, Inc. All rights reserved.
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, DR2

carbogen, and
Fractional Blood Volume
Small and large subcutaneous, and orthotopic PC3 LN3 tumors
exhibited significantly different mean baseline R2
, and DR2

carbogen
(Fig. 1A, B). The mean baseline R2
 was significantly faster in the Copyright © 2016 Wolters Klu
small subcutaneous tumor cohort than in the large subcutaneous or
FIGURE 1. Summary of (A) baseline R2
, (B) carbogen-induced DR2
,
and (C) fractional blood volume determined from the cohorts of small
(n¼6) and large (n¼6) subcutaneous, and orthotopically propagated
PC3 LN3 prostate cancer xenografts (n¼5). Values are mean1 s.e.m,
P<0.05, Student’s 2-tailed unpaired t test.
 2016 Wolters Kluwer Health, Inc. All rights reserved.orthotopic PC3 LN3 tumors, and orthotopic tumors exhibited a
significantly slower baseline R2
 than the large subcutaneous tumors.
Mean DR2

carbogen was negative in the small subcutaneous tumor
cohort, and positive in both the large subcutaneous and orthotopic
cohorts. The mean fractional tumor blood volume was significantly
greater in the small subcutaneous tumors than the large subcutaneous
and orthotopic tumors (Fig. 1C). Fractional blood volume was
significantly higher in the orthotopic cohort, than the large subcu-
taneous group.
Combined Carbogen-Ultrasmall Superparamagnetic
Iron Oxide Imaging Response Categories
Representative CUSPIO RGB maps, which show the spatial
distributionofR2
 responses to carbogenbreathing andUSPIOparticle
injection, for small and large subcutaneous, and orthotopic PC3 LN3
tumors are shown inFig. 2.Visual inspection of theRGBmaps fromall
tumor cohorts showed a heterogeneous spatial distribution of the 5
CUSPIO response categories. The RGB maps from each of the PC3
LN3 tumor cohorts revealed a differing spatial distribution of CUSPIO
response categories. The large subcutaneous tumors typically showed
a central nonresponding region, which were less prevalent in the small
or orthotopic tumors. Orthotopic tumors appeared to have larger
continuous regions of green and cyan voxels contained in one area
of the tumor, whereas the subcutaneous tumors exhibited several
smaller, more discrete regions of green voxels distributed across the
tumor. A greater incidence of yellow voxels was noticeable in the
orthotopic tumor RGB maps, than the subcutaneous tumor cohorts,
which agrees with the quantified CUSPIO data.
The predicted predominant response of tumor tissue to carbogen
breathing and USPIO particles is a negative DR2

carbogen followed by
positive DR2

USPIO, represented by cyan voxels on the RGB maps. It
was therefore interesting that the RGB maps for all the PC3 LN3
tumors showed regions where there was significant DR2

carbogen but
no significant DR2

USPIO (red and blue voxels), and regions where
there was no significant DR2

carbogen followed by a significant
DR2

USPIO (green voxels). The CUSPIO response categories in
PC3 LN3 prostate tumors were separated spatially into regions that
were larger than a single voxel (0.23 0.23mm2), but small com-
pared with the entire tumor ROI.2
To quantify the spatial information displayed in the CUSPIO
RGB maps, the percentage of tumor ROI voxels that exhibited each
R2
 response category was calculated, and is summarized in Table 1.
No significant difference in any of the 5 CUSPIO response categories
was measured between the small and large subcutaneous PC3 LN3
tumor cohorts. A significantly greater percentage of the tumor ROI
was occupied by red and yellow voxels in the orthotopic cohort, than
the small subcutaneous tumors. A significantly smaller number of
blue voxels was measured in the orthotopic cohort, than the small
subcutaneous tumors.
Hoechst 33342 Fluorescence Microscopy
Composite fluorescence images of Hoechst 33342 uptake from
small and large subcutaneous tumors and an orthotopic PC3 LN3
xenograft are shown in Fig. 3A. Hoechst 33342 uptake was hetero-
geneous in all three tumor cohorts, and visually greater in the center of
the small subcutaneous and orthotopic tumors. Significantly greater
mHPAwas determined in both the small subcutaneous and orthotopic
cohorts than the large subcutaneous tumor group (Fig. 3B).
DISCUSSION
In this study, the CUSPIO imaging protocol was used to
investigate how tumor size and site of implantation affect thewer Health, Inc. All rights reserved.
vascular characteristics and function of PC3 LN3 prostate tumors
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FIGURE 2. CUSPIO RGB maps from the three axial slices obtained from representative (A) small subcutaneous, (B) large subcutaneous, and (C)
orthotopic PC3 LN3 prostate xenografts. The key shows the color-coded CUSPIO response categories.
Burrell et al Topics in Magnetic Resonance Imaging  Volume 25, Number 5, October 2016in vivo. PC3 LN3 prostate tumors were propagated subcutaneously
and orthotopically, and the subcutaneous tumors were separated into
small and large tumor cohorts. All tumors were then imaged using the
CUSPIO imaging protocol. It was hypothesized that tumor size and
site of implantation would affect the resulting vascular phenotype.
Tumor Baseline R2
, DR2

carbogen, and Fractional
Blood Volume
As the oxygenation of hemoglobin is proportional to the arterial
blood paO2, and therefore in equilibrium with tissue pO2, measure-
ments of baseline R2
 have been exploited as a sensitive biomarker of
hypoxia.11,24 The significantly faster baseline R2
 determined in the
small subcutaneous PC3 LN3 xenografts suggests that tumors from
this cohort were the most hypoxic. In order to progress, such small
tumors are likely to initiate a strong hypoxia-driven vasculogenic
drive, with associated increase expression of vascular endothelial
growth factor (VEGF), resulting in immature, unstable vasculature
transporting predominantly deoxygenated blood, resulting in a rela-
tively faster R2
. Magnetic field inhomogeneties arising from Copyright © 2016 Wolters Kluw
susceptibility artifacts caused by air-tissue interfaces, which may
240 | www.topicsinmri.combe more prevalent when imaging such small tumors, would also
impact on the R2
 measurement, though the use of dental paste to
immobilize the tumors should limit this.19
Tumor DR2

carbogen was significantly different across all three
tumor cohorts, suggesting that both the size and site of implantation
of the PC3 LN3 tumors had an effect on their incipient hemodynamic
vasculature.25 Differences in functional vasculature between subcu-
taneous and orthotopic tumors reflect a difference in the interaction
of tumor vessels with the host vasculature, or differential pericyte/
endothelial cell recruitment by different host tissues.26,27 Tumor-
stromal interactions are powerful determinants of vascular growth
factor expression, and therefore the resulting vasculature.26,28
Furthermore, growth factor receptor expression differs in endothelial
cells from different tissues, which may be reflected in these differ-
ences in MRI vascular biomarkers.29 Differences between small and
large subcutaneous xenografts is likely a consequence of more
mature vasculature, higher interstitial pressure, and increasing lack
of vascular hierarchy associated with larger tumours.30 The small
subcutaneous tumor cohort exhibited a negative DR2

carbogen, indica-
11er Health, Inc. All rights reserved.
tive of a functional, erythrocyte perfused vascular network.
 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. CUSPIO Mean Fractional Response Categories for Small and Large Subcutaneous, and Orthotopic PC3 LN3 Prostate
Tumors
DR2

carbogen þve DR2carbogen ve DR2carbogen¼ 0 DR2carbogen ve DR2carbogen þve
DR2

USPIO þve DR2USPIOþve DR2USPIO þve DR2USPIO¼ 0 DR2USPIO¼ 0
Small 10.1 5 14.3 4 22.2 6 10.9 5 17.5 5
Large 11.1 1 9.0 2 25.8 4 14.0 3 9.6 2
Orthotopic 26.8 5 11.0 2 22.5 3 17.7 3 5.9 2
Values are mean % of the total tumor ROI 1 s.e.m.
P< 0.05, Student’s 2-tailed unpaired t test, between small and orthotopic tumors.
Topics in Magnetic Resonance Imaging  Volume 25, Number 5, October 2016 CUSPIO Imaging of Subcutaneous and Orthotopic TumorsCombined with their significantly faster baseline R2
, these data
suggest that the small PC3 LN3 tumors were hypoxic at baseline, and
become less hypoxic during carbogen breathing.31 The positive
DR2

carbogen measured in the large subcutaneous and orthotopic
tumors can be explained by the vascular steal effect, that is, the
distribution of blood away from the tumor vascular bed by the
systemic vasculature.32,33 From this, it can be inferred that both
these cohorts have less hemodynamic vasculature than the small
subcutaneous tumors.
The significantly greater fractional blood volume in the small
subcutaneous PC3 LN3 tumors is consistent with previous work
showing that small tumors are often better perfused.30 Vasculogenesis
in small tumors provides a nutritive blood supply, but which may not
meet the evolving metabolic adaptation/demands of the cancer cells,
hence theirmarkedly elevated hypoxia. As tumors progress, their rapid
growth outpaces angiogenesis, resulting in a more poorly organized
vascular hierarchy that, in conjunction with raised interstitial fluid
pressure, causes plasma perfusion as a percentage of tumor volume to
decrease.27 Hoechst 33342 uptake showed close agreement with the
MRI-derived fractional blood volume results from the same subcu-
taneous tumors, providing further validation of this imaging bio-
marker.34,35 Orthotopic PC3 LN3 tumors exhibited a significantly
larger blood volume than the large subcutaneous tumors, reflecting
differences in vascular phenotype associated with the different tumor
microenvironments, as there was no significant difference in the mean
volumes of these tumor cohorts. This is consistent with the elevated
vascular volume, measured by MRI, in orthotopic, compared with
subcutaneous, PC3 tumors.36 These differences may arise from tumor
cell interactions with stromal cells from the prostate compared with
dermal site, or because of differential angiogenic growth factor
receptor expression in the different tissues.
Combined Carbogen-Ultrasmall Superparamagnetic
Iron Oxide Imaging
The CUSPIO RGB maps from all 3 PC3 LN3 tumor cohorts
 Copyright © 2016 Wolters Klu
revealed regions wherein R2 changed significantly (þ or -) during
FIGURE 3. A, Composite fluorescence microscopy images showing Hoech
orthotopic PC3 LN3 prostate xenografts. B, Summary of Hoechst 33342 p
fluorescence microscopy in small (n¼6) and large (n¼6) subcutaneous
1 s.e.m., P<0.05, Student’s 2-tailed unpaired t test.
 2016 Wolters Kluwer Health, Inc. All rights reserved.carbogen breathing, but did not change after administration of
USPIO particles (blue and red voxels), as previously observed in
other tumor models.2 This suggests that these regions have experi-
enced vascular shutdown in the 15-minute period between carbogen
inhalation and injection of USPIO particles. RGB maps from all
tumors also showed a heterogeneous spatial distribution of
DR2

USPIO (green) voxels, which is indicative of heterogeneous
plasma perfusion. Green CUSPIO voxels have been previously
shown to have a close spatial association with Hoechst 33342
uptake.2 RGB maps from the orthotopic PC3 LN3 tumors showed
localized regions of green and cyan voxels, compared with more
heterogeneous distribution seen in the subcutaneous tumors. This
may reflect a difference in vascular supply to the tumors, resulting
from the different microenvironments.9
There was no significant difference in any of the CUSPIO DR2

response categories between the small and large subcutaneous
tumors, suggesting a similar incidence of transient hypoxia and
levels of plasma perfusion in these 2 cohorts. Tumor size may
therefore only weakly influence the incidence of intermittent blood
flow and plasma perfusion, compared with tumor-stroma interactions
and the effect of site of implantation. The similarity in the yellow and
cyan CUSPIO response categories in the small and large tumors
suggests that these two models had similarly patent, functional
vasculature.
Quantitation of the CUSPIO categories revealed that orthotopic
PC3 LN3 tumors exhibited a significantly greater percentage of red
and yellow voxels, and a significantly smaller number of blue voxels,
than the small subcutaneous cohort. The lower number of blue voxels
suggests a lower incidence of transient hypoxia in the orthotopic
tumors. The greater number of yellow voxels also suggests that the
orthotopic tumors experienced a lower incidence of intermittent
blood flow, as more of the tumor remained perfused throughout
the whole CUSPIO imaging session than the small subcutaneous
tumors. The greater percentage of red voxels, combined with the
higher incidence of yellow voxels, in the orthotopic tumors, maywer Health, Inc. All rights reserved.
indicate a greater incidence of vascular steal. This inference aligns
st 33342 uptake in representative small and large subcutaneous, and
erfused area (HPA%), which represents plasma perfusion, measured by
, and orthotopic (n¼5) PC3 LN3 prostate tumors. Values are mean
www.topicsinmri.com | 241
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
carbogen measured in the orthotopic
tumors, compared with the negative mean DR2

carbogen measured
in the small subcutaneous cohort. Numerous factors are important
determinants of the vascular phenotype that develops in tumors,
including VEGF expression, endothelial cell VEGF receptor expres-
sion, and platelet-derived growth factor receptor (PDGFR-b) expres-
sion, and are all influenced by tumor-stroma interactions. The
differences in CUSPIO response categories measured between small
subcutaneous and orthotopic PC3 LN3 tumors may therefore reflect
differences in pericyte coverage and vascular density in these two
models, and whichmay also be influenced by the vascular bed at each
anatomical site.26,28,37,38
Efficient tumor plasma perfusion is a key determinant of drug
delivery, so a clear understanding on the extent, patency, and spatial
distribution of functional tumor vasculature in vivo provided by
techniques such as CUSPIO imaging is imperative for appropriate
tumor model selection when designing pre-clinical therapy trials.
Carbogen inhalation has been used both clinically and pre-clinically
to increase drug uptake in solid tumors through hypercapnia-induced
vasodilation.39–43 The potential to use CUSPIO imaging to non-
invasively assess the degree and heterogeneity of vascular function-
ality, tumor oxygenation, and vascular shutdown will impact on both
chemotherapy and radiotherapy, which generally exhibit higher
efficacy in well oxygenated tumor tissue.44 Differences in vascular
architecture and function arising in subcutaneous and orthotopic
models also has implications for the sensitivity of a model in which to
evaluate novel anti-angiogenic drugs, and targeted agents whose
mode of action is predicted to elicit an anti-angiogenic effect.3
In conclusion, the vascular structure and function of tumor
xenografts, derived from a PC3 LN3 human prostate cell line, was
shown to be dependent on both the site of implantation and relative
tumor size using the CUSPIO imaging protocol. Significant differ-
ences in DR2

carbogen, fractional blood volume, and CUSPIO
response categories were determined between small and large sub-
cutaneous, and orthotopically propagated PC3 LN3 prostate cancer
xenografts.
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